A Novel drug delivery for AIDS
In order to achieve distinct therapeutic objectives and advantages the technology suggests an alternative pharmaceutical composition i.e an antiretroviral drug encapsulated in a vesicle. This pharmaceutical composition is considered to obtain a reduction in the frequency of dosing, a reduction in the amount of drug consumed by the patient. The pharmaceutical composition comprising of vesicles, liposomes are lipid bilayers surrounding an aqueous space. The drug substances are encapsulated within the liposomes. The ability of liposomes consisting of components other than phospholipids and cholesterol or their semisynthetic derivatives to enhance the encapsulation of bioactive substances provides new promising perspectives for establishing new, efficient and stable carriers for drug delivery. These vesicles protect the entrapped molecules and enhance the permeability of the drug into the body cells. Liposomes as drug delivery systems are very versatile in that they can be tailored to suit the delivery of various drug molecules. The designed vesicles can be incorporated into the biological system via different routes of administration. The technology facilitates controlled & direct delivery of the drug into the systemic circulation, along with the maintenance of MIC (Minimum viral Inhibitory Concentration) throughout the therapy, and to facilitate entry of drugs to the target cells of the immune system. It overcomes first pass and other pre systemic drug degradation of biologically active ingredients. It also minimizes the dose dependent debilitating toxic effects which generally result in termination of the treatment. These vesicular formulations improve the bioavailability, biodistribution, permeation, bioprotection and control the release of the drug.
Area of Application: Pharma industry.
Keywords: drug delivery, AIDS.
Advantages: Facilitates controlled & direct delivery of the drug. Reduces frequency of dose. Overcomes first pass and other pre systemic drug degradation of biologically active ingredients. Reduction in the amount of drug consumed by the patient. Vesicles can be incorporated into the biological system via different routes of administration. Minimizes the dose dependent debilitating toxic effects. Liposomal formulation developed has therapeutic superiority. Maintains Minimum Viral Inhibitory Concentration throughout the therapy.
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection: Patent in Progress
Transfer Terms: Technology Licensing
Target Countries: India
Estimated cost (US$):
Upload any relevant document:
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
Zip/Pin Code: 380054